Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report.

Cancer reports (Hoboken, N.J.) - 1 Jun 2025

Wang Li, Wu Jiaqi, Shao Ping, Bao Wuping, Mao Lin, Pan Zhendong, Bao Aihua, Zhang Min, Wu Zhenghua, Fan Guorong

Abstract excerpt

BACKGROUND: Although the presence of Kirsten murine sarcoma virus (KRAS) mutations predicts a failure of non-small cell carcinoma (NSCLC) patients to benefit from epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy it may be more sensitive to programmed combination therapy of programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors + anti-angiogenesis. Recent treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins p21(ras)

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 40488279
DOI: 10.1002/cnr2.70186
PMCID: PMC12147042

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report.PMID 40488279Read ↗

An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti- angiogenic agents for therapy: a case reportSemantic proximity Read ↗

An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti-angiogenic agents for therapy: a case reportSemantic proximity Read ↗

[Annual therapeutic advances in advanced non-small cell lung cancer in 2024].Semantic proximity Read ↗

Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.Semantic proximity Read ↗

Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small-cell lung cancer: a systematic review and network meta-analysis.Semantic proximity Read ↗

Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study.Semantic proximity Read ↗

Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.Semantic proximity Read ↗

Targeted combination of Bevacizumab demonstrates superior efficacy for stage IV Adenocarcinoma of the lung with EGFR mutation: A Real World StudySemantic proximity Read ↗

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.Semantic proximity Read ↗

Differential Benefit of Immune Checkpoint Blockade by<i>KRAS</i>Mutation Status in Metastatic Lung Adenocarcinoma: Validation from an Extended Swedish CohortSemantic proximity Read ↗

Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.Semantic proximity Read ↗

Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.